120 related articles for article (PubMed ID: 16684712)
1. Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans.
Sakuda S; Akabane T; Teramura T
Xenobiotica; 2006 Apr; 36(4):331-40. PubMed ID: 16684712
[TBL] [Abstract][Full Text] [Related]
2. Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey.
Nishimura T; Amano N; Kubo Y; Ono M; Kato Y; Fujita H; Kimura Y; Tsuji A
Drug Metab Dispos; 2007 Aug; 35(8):1275-84. PubMed ID: 17470527
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the intestinal permeability and first-pass metabolism of drugs in cynomolgus monkeys using single-pass intestinal perfusion.
Takahashi M; Washio T; Suzuki N; Igeta K; Yamashita S
Biol Pharm Bull; 2010; 33(1):111-6. PubMed ID: 20045946
[TBL] [Abstract][Full Text] [Related]
4. The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans.
Takahashi M; Washio T; Suzuki N; Igeta K; Yamashita S
J Pharm Sci; 2009 Nov; 98(11):4343-53. PubMed ID: 19230019
[TBL] [Abstract][Full Text] [Related]
5. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
6. Prediction of the intestinal first-pass metabolism of CYP3A substrates in humans using cynomolgus monkeys.
Nishimuta H; Sato K; Mizuki Y; Yabuki M; Komuro S
Drug Metab Dispos; 2010 Nov; 38(11):1967-75. PubMed ID: 20702772
[TBL] [Abstract][Full Text] [Related]
7. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.
Thummel KE; O'Shea D; Paine MF; Shen DD; Kunze KL; Perkins JD; Wilkinson GR
Clin Pharmacol Ther; 1996 May; 59(5):491-502. PubMed ID: 8646820
[TBL] [Abstract][Full Text] [Related]
8. A comparison of pharmacokinetics between humans and monkeys.
Akabane T; Tabata K; Kadono K; Sakuda S; Terashita S; Teramura T
Drug Metab Dispos; 2010 Feb; 38(2):308-16. PubMed ID: 19910513
[TBL] [Abstract][Full Text] [Related]
9. Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys.
Ogasawara A; Kume T; Kazama E
Drug Metab Dispos; 2007 Mar; 35(3):410-8. PubMed ID: 17142564
[TBL] [Abstract][Full Text] [Related]
10. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.
Lappin G; Kuhnz W; Jochemsen R; Kneer J; Chaudhary A; Oosterhuis B; Drijfhout WJ; Rowland M; Garner RC
Clin Pharmacol Ther; 2006 Sep; 80(3):203-15. PubMed ID: 16952487
[TBL] [Abstract][Full Text] [Related]
11. Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation.
Koyanagi T; Nakanishi Y; Murayama N; Yamaura Y; Ikeda K; Yano K; Uehara S; Utoh M; Kim S; Uno Y; Yamazaki H
Xenobiotica; 2015 Apr; 45(4):312-21. PubMed ID: 25364857
[TBL] [Abstract][Full Text] [Related]
12. Toxicokinetics of bisphenol A in rats, monkeys and chimpanzees by the LC-MS/MS method.
Tominaga T; Negishi T; Hirooka H; Miyachi A; Inoue A; Hayasaka I; Yoshikawa Y
Toxicology; 2006 Sep; 226(2-3):208-17. PubMed ID: 16914249
[TBL] [Abstract][Full Text] [Related]
13. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
14. Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling.
Shida S; Utoh M; Murayama N; Shimizu M; Uno Y; Yamazaki H
Xenobiotica; 2015; 45(10):881-6. PubMed ID: 26075833
[TBL] [Abstract][Full Text] [Related]
15. Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans.
Nishimuta H; Sato K; Mizuki Y; Yabuki M; Komuro S
Drug Metab Pharmacokinet; 2011 Jun; 26(3):300-6. PubMed ID: 21383522
[TBL] [Abstract][Full Text] [Related]
16. 4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys.
Li K; Zhao S; Zhang L; Wu X; Shu P; Wang Y; Feng H; Gu Z; Han Hsu H
Drug Metab Dispos; 2014 May; 42(5):839-43. PubMed ID: 24595680
[TBL] [Abstract][Full Text] [Related]
17. Characterization of gastrointestinal drug absorption in cynomolgus monkeys.
Takahashi M; Washio T; Suzuki N; Igeta K; Fujii Y; Hayashi M; Shirasaka Y; Yamashita S
Mol Pharm; 2008; 5(2):340-8. PubMed ID: 18247527
[TBL] [Abstract][Full Text] [Related]
18. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
[TBL] [Abstract][Full Text] [Related]
19. Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats.
Higashikawa F; Murakami T; Kaneda T; Kato A; Takano M
J Pharm Pharmacol; 1999 Jan; 51(1):67-72. PubMed ID: 10197420
[TBL] [Abstract][Full Text] [Related]
20. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
